BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 23690408)

  • 1. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
    Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates in multiple myeloma: an updated network meta-analysis.
    Mhaskar R; Kumar A; Miladinovic B; Djulbegovic B
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003188. PubMed ID: 29253322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
    Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic options in the management of myeloma bone disease.
    Berenson JR
    Semin Oncol; 2010 Jun; 37 Suppl 1():S20-9. PubMed ID: 20682368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
    Berenson JR; Hillner BE; Kyle RA; Anderson K; Lipton A; Yee GC; Biermann JS;
    J Clin Oncol; 2002 Sep; 20(17):3719-36. PubMed ID: 12202673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate therapy in multiple myeloma: past, present, future.
    Jantunen E
    Eur J Haematol; 2002; 69(5-6):257-64. PubMed ID: 12460229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
    Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
    Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates in multiple myeloma.
    Berenson JR
    Cancer; 1997 Oct; 80(8 Suppl):1661-7. PubMed ID: 9362433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
    Morgan GJ
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S24-30. PubMed ID: 21353177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of bone disease in multiple myeloma.
    Terpos E; Berenson J; Raje N; Roodman GD
    Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
    Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
    Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group.
    Terpos E; Zamagni E; Lentzsch S; Drake MT; García-Sanz R; Abildgaard N; Ntanasis-Stathopoulos I; Schjesvold F; de la Rubia J; Kyriakou C; Hillengass J; Zweegman S; Cavo M; Moreau P; San-Miguel J; Dimopoulos MA; Munshi N; Durie BGM; Raje N;
    Lancet Oncol; 2021 Mar; 22(3):e119-e130. PubMed ID: 33545067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Mitsiades CS; Rosenblatt J; Mahindra A; Raje N; Munshi N; Anderson KC
    Eur J Haematol; 2012 Jan; 88(1):1-7. PubMed ID: 21991938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
    Terpos E; Sezer O; Croucher PI; García-Sanz R; Boccadoro M; San Miguel J; Ashcroft J; Bladé J; Cavo M; Delforge M; Dimopoulos MA; Facon T; Macro M; Waage A; Sonneveld P;
    Ann Oncol; 2009 Aug; 20(8):1303-17. PubMed ID: 19465418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in imaging and the management of myeloma bone disease.
    Terpos E; Moulopoulos LA; Dimopoulos MA
    J Clin Oncol; 2011 May; 29(14):1907-15. PubMed ID: 21483016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.